Michelle Ward
@michelle-c-ward.bsky.social
Functional genomicist & Assistant Professor at The University of Texas Medical Branch at Galveston. https://www.ward-lab.org/
Thank you to the reviewers for helping us focus and strengthen the manuscript, and the editors for a smooth publication process. [3/3]
October 29, 2025 at 5:15 AM
Thank you to the reviewers for helping us focus and strengthen the manuscript, and the editors for a smooth publication process. [3/3]
We found large-scale rewiring of the chromatin landscape across related drugs that coincide with TOP2B binding, neighboring gene expression changes and loci associated with atrial fibrillation. [2/3]
October 29, 2025 at 5:15 AM
We found large-scale rewiring of the chromatin landscape across related drugs that coincide with TOP2B binding, neighboring gene expression changes and loci associated with atrial fibrillation. [2/3]
We believe this work provides insight into the role of topoisomerase II beta in gene regulation, and cancer patient risk for cardiovascular disease. [4/4]
July 24, 2025 at 11:52 PM
We believe this work provides insight into the role of topoisomerase II beta in gene regulation, and cancer patient risk for cardiovascular disease. [4/4]
We compared the effects of CX and DOX in human cardiomyocytes. CX is 20-fold less toxic than DOX and induces an order of magnitude fewer changes in gene expression despite a shared target. However, CX-induced transcriptional changes are shared with DOX. [3/4]
July 24, 2025 at 11:52 PM
We compared the effects of CX and DOX in human cardiomyocytes. CX is 20-fold less toxic than DOX and induces an order of magnitude fewer changes in gene expression despite a shared target. However, CX-induced transcriptional changes are shared with DOX. [3/4]
DOX is an effective anti-cancer drug. However, it inhibits the DNA topology regulator topoisomerase II beta in the heart leading to increased risk for cardiovascular disease. CX-5461 is a promising novel anti-cancer compound that was recently shown to target the same protein. [2/4]
July 24, 2025 at 11:52 PM
DOX is an effective anti-cancer drug. However, it inhibits the DNA topology regulator topoisomerase II beta in the heart leading to increased risk for cardiovascular disease. CX-5461 is a promising novel anti-cancer compound that was recently shown to target the same protein. [2/4]
Congrats Anat, Nehal and Guy!
June 17, 2025 at 4:39 AM
Congrats Anat, Nehal and Guy!